• Yuexin joined Andera Life Sciences as investment director in 2021.
  • Before joining Andera, Yuexin was vice president at 3H Health Investment Management Hong Kong and Shanghai where he made leading contributions to biotech portfolio including InnoCare Pharma (9969.HK), Keymed Biosciences (2162.HK) and EdiGene. His sector and management perspectives form through collaborations with entrepreneurs over the years, and earlier through life-cycle management at Merck, business development at Biotheranostics and investment research at Mérieux Développement.
  • Yuexin holds PharmD from Shanghai Jiao Tong University and MSc in Management from HEC.
  • Yuexin speaks Chinese, English and French.

42 is a new school